174 related articles for article (PubMed ID: 27748274)
1. Level of PAX5 in differential diagnosis of non-Hodgkin's lymphoma.
Bharti B; Shukla S; Tripathi R; Mishra S; Kumar M; Pandey M; Mishra R
Indian J Med Res; 2016 May; 143(Supplement):S23-S31. PubMed ID: 27748274
[TBL] [Abstract][Full Text] [Related]
2. Isoforms of Pax5 and co-regulation of T- and B-cells associated genes influence phenotypic traits of ascetic cells causing Dalton's lymphoma.
Bharti B; Mishra R
Biochim Biophys Acta; 2011 Dec; 1813(12):2071-8. PubMed ID: 21854813
[TBL] [Abstract][Full Text] [Related]
3. Expression of the PAX5/BSAP transcription factor in haematological tumour cells and further molecular characterization of the t(9;14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma.
Hamada T; Yonetani N; Ueda C; Maesako Y; Akasaka H; Akasaka T; Ohno H; Kawakami K; Amakawa R; Okuma M
Br J Haematol; 1998 Aug; 102(3):691-700. PubMed ID: 9722295
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Pax5 expression and comparison with BLA.36 and CD79αcy in feline non-Hodgkin lymphoma.
Felisberto R; Matos J; Alves M; Cabeçadas J; Henriques J
Vet Comp Oncol; 2017 Dec; 15(4):1257-1268. PubMed ID: 27549353
[TBL] [Abstract][Full Text] [Related]
5. [Expression of the transcription factor PAX5 in childhood acute leukemic cells].
Zhang B; Tie LJ; Ye QD; Gu LJ; Tang JY; Yuan XL; Shen LS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb; 14(1):6-10. PubMed ID: 16584581
[TBL] [Abstract][Full Text] [Related]
6. PAX8 and PAX5 are differentially expressed in B-cell and T-cell lymphomas.
Morgan EA; Pozdnyakova O; Nascimento AF; Hirsch MS
Histopathology; 2013 Feb; 62(3):406-13. PubMed ID: 23163626
[TBL] [Abstract][Full Text] [Related]
7. Pax5 immunostaining in paraffin-embedded sections of canine non-Hodgkin lymphoma: a novel canine pan pre-B- and B-cell marker.
Willmann M; Müllauer L; Guija de Arespacochaga A; Reifinger M; Mosberger I; Thalhammer JG
Vet Immunol Immunopathol; 2009 Apr; 128(4):359-65. PubMed ID: 19100628
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of the B-cell lineage markers CD20, CD79a, PAX5, and CD19 in paraffin-embedded tissues from lymphoid neoplasms.
Adams H; Liebisch P; Schmid P; Dirnhofer S; Tzankov A
Appl Immunohistochem Mol Morphol; 2009 Mar; 17(2):96-101. PubMed ID: 18838917
[TBL] [Abstract][Full Text] [Related]
9. Non-Hodgkin's lymphoma by immunohistochemistry.
Akhter A; Saleheen MS; Hussain M; Majid N; Rahman MR; Shermin S; Rajib RC; Huda MM; Haque N
Mymensingh Med J; 2015 Jan; 24(1):108-14. PubMed ID: 25725676
[TBL] [Abstract][Full Text] [Related]
10. Clinical and prognostic analysis of 125 cases of non-Hodgkin's lymphoma.
Liu L; Zhang M; Zou P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):547-50. PubMed ID: 18549626
[TBL] [Abstract][Full Text] [Related]
11. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5.
Bousquet M; Broccardo C; Quelen C; Meggetto F; Kuhlein E; Delsol G; Dastugue N; Brousset P
Blood; 2007 Apr; 109(8):3417-23. PubMed ID: 17179230
[TBL] [Abstract][Full Text] [Related]
12. [Imaging features of Waldeyer's ring in non-Hodgkin's lymphoma and its clinical significance].
Huang SF; Zhang LF; He X; Shen WR; Gu ZY
Ai Zheng; 2004 Nov; 23(11):1325-8. PubMed ID: 15522183
[TBL] [Abstract][Full Text] [Related]
13. Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway.
Yu D; Allman D; Goldschmidt MH; Atchison ML; Monroe JG; Thomas-Tikhonenko A
Blood; 2003 Mar; 101(5):1950-5. PubMed ID: 12406913
[TBL] [Abstract][Full Text] [Related]
14. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis.
Chung EY; Psathas JN; Yu D; Li Y; Weiss MJ; Thomas-Tikhonenko A
J Clin Invest; 2012 Jun; 122(6):2257-66. PubMed ID: 22546857
[TBL] [Abstract][Full Text] [Related]
15. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis.
Rueffer U; Josting A; Franklin J; May M; Sieber M; Breuer K; Engert A; Diehl V;
J Clin Oncol; 2001 Apr; 19(7):2026-32. PubMed ID: 11310450
[TBL] [Abstract][Full Text] [Related]
16. [Apoptosis-antagonizing protein Bcl-2 expression, distribution in non-Hodgkin's lymphoma and its clinical significance].
Chen X; Huang G; Wang W
Zhonghua Zhong Liu Za Zhi; 1997 Mar; 19(2):140-2. PubMed ID: 10743081
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Utility of PAX5 in Hodgkin and Non-Hodgkin Lymphoma: A Study from Northern India.
Johri N; Patne SC; Tewari M; Kumar M
J Clin Diagn Res; 2016 Aug; 10(8):XC04-XC07. PubMed ID: 27656544
[TBL] [Abstract][Full Text] [Related]
18. PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia.
Tiacci E; Pileri S; Orleth A; Pacini R; Tabarrini A; Frenguelli F; Liso A; Diverio D; Lo-Coco F; Falini B
Cancer Res; 2004 Oct; 64(20):7399-404. PubMed ID: 15492262
[TBL] [Abstract][Full Text] [Related]
19. The t(9;14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma.
Ohno H; Ueda C; Akasaka T
Leuk Lymphoma; 2000 Feb; 36(5-6):435-45. PubMed ID: 10784387
[TBL] [Abstract][Full Text] [Related]
20. [Differential diagnostic and prognostic significance of the activity of nucleolar organizer region in non-Hodgkin's malignant lymphoma].
Bukaeva IA; Raĭkhlin NT; Probatova NA; Smirnova EA; Tulitsyn NN; Sholokhova EN
Klin Lab Diagn; 1997 Oct; (10):37-8. PubMed ID: 9417324
[No Abstract] [Full Text] [Related]
[Next] [New Search]
